<SEC-DOCUMENT>0001213900-25-120089.txt : 20251210
<SEC-HEADER>0001213900-25-120089.hdr.sgml : 20251210
<ACCEPTANCE-DATETIME>20251210161523
ACCESSION NUMBER:		0001213900-25-120089
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251210
DATE AS OF CHANGE:		20251210

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Clearmind Medicine Inc.
		CENTRAL INDEX KEY:			0001892500
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93839
		FILM NUMBER:		251562161

	BUSINESS ADDRESS:	
		STREET 1:		101-1220 WEST 6TH AVENUE
		CITY:			VANCOUVER, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V6H1A5
		BUSINESS PHONE:		972-54-5704749

	MAIL ADDRESS:	
		STREET 1:		101-1220 WEST 6TH AVENUE
		CITY:			VANCOUVER, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V6H1A5

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			L.I.A. Pure Capital Ltd
		CENTRAL INDEX KEY:			0001749628
		ORGANIZATION NAME:           	
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		20 RAOUL WALENBERG ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-7175777

	MAIL ADDRESS:	
		STREET 1:		20 RAOUL WALENBERG ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: L.I.A. Pure Capital Ltd -->
          <cik>0001749628</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Shares, no par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/03/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001892500</issuerCik>
        <issuerName>Clearmind Medicine Inc.</issuerName>
        <issuerCusip>185053402</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>101 - 1220 West 6th Avenue</com:street1>
          <com:city>Vancouver</com:city>
          <com:stateOrCountry>A1</com:stateOrCountry>
          <com:zipCode>V6H1A5</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>L.I.A. Pure Capital Ltd.</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>L3</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>5980397.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>5980397.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>5980397.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.97</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>*Percentage calculated based on 59,991,852 common shares, no par value per share, of Clearmind Medicine Inc. (the "Issuer") issued and outstanding, as reported by the Issuer in prospectus supplement filed pursuant to Rule 424(b)(5) as filed with the Securities and Exchange Commission on December 3, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Clearmind Medicine Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>101 - 1220 West 6th Avenue, Vancouver, British Columbia V6H1A5</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>L.I.A. Pure Capital Ltd.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>20 Raoul Wallenberg Street, Tel Aviv, Israel 6971916</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Israel</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.</amountBeneficiallyOwned>
        <classPercent>See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>L.I.A. Pure Capital Ltd.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Kfir Silberman</signature>
        <title>Kfir Silberman/Chief Executive Officer</title>
        <date>12/10/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
